MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy


September 17, 2020MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria.

August 04, 2020MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®.

June 10, 2020MYR Pharmaceuticals has incorporated its first European subsidiary in France.

May 29, 2020 - MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections.

April 14, 2019 - Interview. Prof. Dr. Med. Heiner Wedemeyer. The International Liver Congress 2019.

April 13, 2019 - ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression both on and off treatment with good tolerability.

April 12, 2019EASL Press Conference 2019. The International Liver Congress 2019.

April 04, 2019MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.

March 05, 2019MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections

October 29, 2018MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta

October 23, 2018MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections

March 27, 2018MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

March 12, 2018 - MYR Pharma Completes MYR 202 Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

February 22, 2018MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B

October 22, 2017 - MYR Pharma presents positive interim results in MYR 202 clinical trial

July - September, 2017 – Several review articles highlight Myrcludex B as a strong contender in the treatment of Hepatitis D and B:

May 26, 2017Myrcludex B becomes one of five new drugs to receive PRIME (PRIority MEdicines) designation in 2017

May 2, 2017Myrcludex B potential in the treatment of Hepatitis D reviewed in Current Opinion in Virology

May 25, 2016Initiation of MYR 203

April 24, 2016 - First results of chronic Hepatitis D treatment with Myrcludex B are published in Journal of Hepatology

April 24, 2016Results of first-in-human application of Myrcludex B are reported in Jounral of Hepatology